These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 35394898)
1. Effects of maternal antibodies in infants on the immunogenicity and safety of inactivated polio vaccine in infants. Gao S; Wei M; Chu K; Li J; Zhu F Hum Vaccin Immunother; 2022 Nov; 18(5):2050106. PubMed ID: 35394898 [TBL] [Abstract][Full Text] [Related]
2. The effect of maternal poliovirus antibodies on the immune responses of infants to poliovirus vaccines. Jia S; Tang R; Li G; Hu Y; Liang Q BMC Infect Dis; 2020 Aug; 20(1):641. PubMed ID: 32867698 [TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of three sequential schedules with Sabin inactivated poliovirus vaccine and bivalent oral poliovirus vaccine in Zhejiang, China: an open-label, randomised, controlled trial. He H; Wang Y; Deng X; Yue C; Tang X; Li Y; Liu Y; Yin Z; Zhang G; Chen Z; Xie S; Wen N; An Z; Chen Z; Wang H Lancet Infect Dis; 2020 Sep; 20(9):1071-1079. PubMed ID: 32442523 [TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of experimental stand-alone trivalent, inactivated Sabin-strain polio vaccine formulations in healthy infants: A randomized, observer-blind, controlled phase 1/2 trial. Cramer JP; Jimeno J; Han HH; Lin S; Hartmann K; Borkowski A; Sáez-Llorens X Vaccine; 2020 Jul; 38(33):5313-5323. PubMed ID: 32563609 [TBL] [Abstract][Full Text] [Related]
5. [Comparing the immunogenicity and safety of sequential inoculation of sIPV followed by bOPV (Ⅰ+Ⅲ) in different dosage forms]. Ye H; Huang T; Ying ZF; Li GL; Che YC; Zhao ZM; Wang JF; Yang XL; Shi L; Jiang RJ; Liu XC; Mo ZJ; Li CG; Yang JS Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Jan; 52(1):43-49. PubMed ID: 29334707 [No Abstract] [Full Text] [Related]
6. Observational analysis of the immunogenicity and safety of various types of spinal muscular atrophy vaccines. Sun G; Wang G; Zhong H Inflammopharmacology; 2024 Apr; 32(2):1025-1038. PubMed ID: 38308795 [TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of sabin-strain based inactivated poliovirus vaccine replacing salk-strain based inactivated poliovirus vaccine: An innovative application of different strain-IPVs replacement. Chen H; Gao Z; Bai S; Liu X; Han S; Xiao Y; Liu F; Yu Y; Sun H; Yang X Vaccine; 2021 Apr; 39(17):2467-2474. PubMed ID: 33810904 [TBL] [Abstract][Full Text] [Related]
8. Immunogenicity evaluation of primary polio vaccination schedule with inactivated poliovirus vaccines and bivalent oral poliovirus vaccine. Xu J; Liu Y; Qiu W; Li W; Hu X; Li X; Fan Q; Tang W; Wang Y; Wang Q; Yao N BMC Infect Dis; 2024 May; 24(1):535. PubMed ID: 38807038 [TBL] [Abstract][Full Text] [Related]
9. Immunogenicity to poliovirus type 2 following two doses of fractional intradermal inactivated poliovirus vaccine: A novel dose sparing immunization schedule. Anand A; Molodecky NA; Pallansch MA; Sutter RW Vaccine; 2017 May; 35(22):2993-2998. PubMed ID: 28434691 [TBL] [Abstract][Full Text] [Related]
10. Surveillance of immunity acquired from poliovirus immunization including vaccination with the Sabin strain-derived inactivated vaccine. Hotta C; Ogawa T; Shirasawa H Hum Vaccin Immunother; 2019; 15(5):1154-1159. PubMed ID: 30676843 [TBL] [Abstract][Full Text] [Related]
11. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis. Ciapponi A; Bardach A; Rey Ares L; Glujovsky D; Cafferata ML; Cesaroni S; Bhatti A Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011260. PubMed ID: 31801180 [TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial. Rivera L; Pedersen RS; Peña L; Olsen KJ; Andreasen LV; Kromann I; Nielsen PI; Sørensen C; Dietrich J; Bandyopadhyay AS; Thierry-Carstensen B Lancet Infect Dis; 2017 Jul; 17(7):745-753. PubMed ID: 28454674 [TBL] [Abstract][Full Text] [Related]
13. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study. O'Ryan M; Bandyopadhyay AS; Villena R; Espinoza M; Novoa J; Weldon WC; Oberste MS; Self S; Borate BR; Asturias EJ; Clemens R; Orenstein W; Jimeno J; Rüttimann R; Costa Clemens SA; Lancet Infect Dis; 2015 Nov; 15(11):1273-82. PubMed ID: 26318714 [TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial. Sáez-Llorens X; Clemens R; Leroux-Roels G; Jimeno J; Clemens SA; Weldon WC; Oberste MS; Molina N; Bandyopadhyay AS Lancet Infect Dis; 2016 Mar; 16(3):321-30. PubMed ID: 26719058 [TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of sequential poliovirus vaccination schedules with different strains of poliomyelitis vaccines in Chongqing, China: a cross-sectional survey. Xu J; Wang Q; Kuang S; Rong R; Zhang Y; Fu X; Tang W Hum Vaccin Immunother; 2021 Jul; 17(7):2125-2131. PubMed ID: 33759702 [TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and Safety of a Sabin Strain-Based Inactivated Polio Vaccine: A Phase 3 Clinical Trial. Hu Y; Wang J; Zeng G; Chu K; Jiang D; Zhu F; Ying Z; Chen L; Li C; Zhu F; Yin W J Infect Dis; 2019 Oct; 220(10):1551-1557. PubMed ID: 30958543 [TBL] [Abstract][Full Text] [Related]
17. [Observation on safety of sequential vaccination schedule of different strain inactivated poliovirus vaccines]. Huang ZY; Sun XD; Liu JC; Li Z; Ren J; Wu LL; Hu JY; Zhang JN Zhonghua Liu Xing Bing Xue Za Zhi; 2019 May; 40(5):565-570. PubMed ID: 31177739 [No Abstract] [Full Text] [Related]
18. Inactivated polio vaccines from three different manufacturers have equivalent safety and immunogenicity when given as 1 or 2 additional doses after bivalent OPV: Results from a randomized controlled trial in Latin America. Lopez-Medina E; Melgar M; Gaensbauer JT; Bandyopadhyay AS; Borate BR; Weldon WC; Rüttimann R; Ward J; Clemens R; Asturias EJ Vaccine; 2017 Jun; 35(28):3591-3597. PubMed ID: 28455172 [TBL] [Abstract][Full Text] [Related]
19. An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6® cell culture platform is immunogenic and safe in a non-human primate model. Bockstal V; Tiemessen MM; Achterberg R; Van Wordragen C; Knaapen AM; Serroyen J; Marissen WE; Schuitemaker H; Zahn R Vaccine; 2018 Nov; 36(46):6979-6987. PubMed ID: 30314910 [TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: A phase II, randomized, dose-finding trial. Chu K; Ying Z; Wang L; Hu Y; Xia J; Chen L; Wang J; Li C; Zhang Q; Gao Q; Hu Y Vaccine; 2018 Oct; 36(45):6782-6789. PubMed ID: 30249424 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]